Abstract: A method performed at a computer system includes: obtaining door lock activation data for a door of a dwelling of the user; obtaining current occupancy data for the dwelling; setting a configuration of a controller for the dwelling, based at least in part on the door lock activation data for the door and the current occupancy data for the dwelling; the first configuration including for each sensor in a set of sensors coupled to the controller, disabling the sensor or disabling alerts from the sensor.

Abstract: This document describes a single-layer air waveguide antenna integrated on a circuit board. The waveguide guides electromagnetic energy through channels filled with air. It is formed from a single layer of material, such as a sheet of metal, metal-coated plastic, or other material with conductive surfaces that is attached to a circuit board. A portion of a surface of the circuit board is configured as a floor of the channels filled with air. This floor is an electrical interface between the circuit board and the channels filled with air. The single layer of material is positioned atop this electrical interface to define walls and a ceiling of the channels filled with air. The single layer of material can be secured to the circuit board in various ways. The cost of integrating an air waveguide antenna on to a circuit board this way may be less expensive than other waveguide-manufacturing techniques.

Abstract: The instant invention is a route to stereospecific 3-substituted 5-membered ring isomers of Formula (A). The final products are useful as agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, gastrointestinal disorders such as irritable bowel syndrome (IBS), inflammation especially arthritis, sleep disorders, premenstrual syndrome, and hot flashes. The invention provides novel routes to synthesize stereoselectively analogs of gabapentin (Neurontin™) of Formulas (I), (II), (III), and (IV) wherein R is C1-C10 alkyl or C3 -C10 cycloalkyl and pharmaceutically acceptable salts thereof.

Abstract: Pro-drug compounds of the formula (I) or (II) and compositions containing them are provided that when administered to humans or other mammals provide an increased duration of active compound in the plasma compared to compounds of corresponding structure in which labile groups are not present. In the above formulae n, P, Q, R1, R2 and R3 are as defined in the specification. The compounds may be used to treat a range of neurological conditions, e.g. epilepsy or pain.